Thyrotropin alfa

Drug Profile

Thyrotropin alfa

Alternative Names: MRrhTSH; Recombinant human thyroid stimulating hormone; rhTSH; rhTSH-M; Thyrogen; Thyrotrophin alpha; Thyrotropin; Thyrotropin alpha for injection

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genzyme Corporation
  • Developer Genzyme Corporation; Odense University Hospital; Sanofi Genzyme
  • Class Diagnostic agents; Pituitary gonadotropins
  • Mechanism of Action Thyrotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thyroid cancer
  • Discontinued Goitre

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 13 May 2015 Discontinued - Phase-II for Goitre in Brazil, Canada, Denmark, France, Germany, Italy and Netherlands (IM, controlled-release)
  • 13 May 2015 Discontinued - Phase-II for Goitre in Denmark (IM, immediate-release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top